Creative Biolabs, a global leader in antibody engineering, today announced its optimization of ADCC and Fc-mediated ...

ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...

MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –– Up to 30% of people with membranous nephropathy progress to ...

Roche reports positive results from phase III MAJESTY study of Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease ...

The main market opportunities in the CLDN18.2-targeted immunotherapy space include next-gen monoclonal antibodies with enhanced efficacy, innovative antibody-drug conjugates (ADCs), advanced CAR-T and ...

Learn why cytotoxicity test failures are common in medical devices and discover systematic approaches to identify root causes ...

The road to Krakou, Poland has begun and the field for the 2026 ADCC World Championships is taking shape. We put together this list as a way for fans of the sport to follow who is in for the biggest ...

The road to ADCC World Championship 2026 officially begins with the first wave of invited athletes and it starts at the very top. As tradition holds, the champions receive automatic invitations, ...

First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...